Overview

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.
Phase:
Phase 2
Details
Lead Sponsor:
Akros Pharma Inc.
Treatments:
Dalcetrapib
Pravastatin